Stemline Therapeutics, Inc. Announces Clinical Trial Results With SL-701, A Phase 2 Therapeutic for High-Grade Glioma, In An Additional Indication: Data To Be Presented At The Society of Neuro-Oncology (SNO) Annual Meeting
Published: Nov 19, 2013
NEW YORK, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that clinical trial results of SL-701, a Phase 2 therapeutic entering registration-directed studies in high-grade glioma (HGG), in an additional indication, low-grade glioma (LGG), will be presented by investigators from the University of Pittsburgh at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) being held in conjunction with the 18th Annual Society for Neuro-Oncology (SNO) meeting in San Francisco, California on November 21-24, 2013. SL-701 is a subcutaneously-administered cancer vaccine comprised of multiple synthetic peptides corresponding to targets on tumor bulk and cancer stem cells (CSCs).
Help employers find you! Check out all the jobs and post your resume.